Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 6/20 | 0.49 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.44 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.44 |
| ▸ | RPS6KB1 | P23443 | 4/20 | 0.43 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | PRKDC | P78527 | 5/20 | 0.40 |
| ▸ | KHK | P50053 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21664240 | 0.90 | ENPP1 (0.46) | ENPP1SIRT2SIRT1SIRT3RPS6KB1 | |
| SCHEMBL21664354 | 0.89 | ENPP1 (0.45) | ENPP1SIRT2SIRT1SIRT3RPS6KB1 | |
| SCHEMBL21664290 | 0.89 | ENPP1 (0.52) | ENPP1SIRT2SIRT1SIRT3PRKDC | |
| SCHEMBL26564103 | 0.86 | RPS6KB1 (0.43) | ENPP1SIRT2SIRT1SIRT3RPS6KB1 | |
| SCHEMBL30562895 | 0.86 | ENPP1 (0.50) | ENPP1SIRT2SIRT1SIRT3PRKDC | |
| SCHEMBL21664291 | 0.86 | ENPP1 (0.50) | ENPP1SIRT2SIRT1SIRT3PRKDC | |
| SCHEMBL21664420 | 0.85 | ENPP1 (0.49) | ENPP1SIRT2SIRT1SIRT3PRKDC | |
| SCHEMBL21664327 | 0.85 | ENPP1 (0.49) | ENPP1SIRT2SIRT1SIRT3PRKDC | |
| SCHEMBL30562896 | 0.85 | ENPP1 (0.49) | ENPP1SIRT2SIRT1SIRT3PRKDC | |
| SCHEMBL26564472 | 0.85 | PRKDC (0.42) | ENPP1RPS6KB1AKT1PRKDCBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3551188-B1 | SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS | SOUTHERN RES INST (US) | 2023-10-18 | — | — | EP | disclosed |
| EP-3551188-B1 | SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS | SOUTHERN RES INST (US) | 2023-10-18 | — | — | EP | disclosed |
| US-11752153-B2 | Substituted quinazoline sulfonamides as thioredoxin interacting protein (TXNIP) inhibitors | SOUTHERN RESEARCH INSTITUTE (US) | 2023-09-12 | — | — | US | disclosed |
| US-11752153-B2 | Substituted quinazoline sulfonamides as thioredoxin interacting protein (TXNIP) inhibitors | SOUTHERN RESEARCH INSTITUTE (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230172932-A1 | SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS | SOUTHERN RESEARCH INSTITUTE (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230172932-A1 | SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS | SOUTHERN RESEARCH INSTITUTE (US) | 2023-06-08 | — | — | US | disclosed |
| US-11524010-B2 | Substituted quinazoline sulfonamides as thioredoxin interacting protein (TXNIP) inhibitors | SOUTHERN RESEARCH INSTITUTE (US) | 2022-12-13 | — | — | US | disclosed |
| US-20210369713-A1 | SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS | SOUTHERN RESEARCH INSTITUTE (US) | 2021-12-02 | — | — | US | disclosed |
| US-20200038402-A1 | SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-02-06 | — | — | US | disclosed |
| EP-3551188-A1 | SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS | Southern Research Institute (US) | 2019-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200038402-A1 | SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS | TXN, TXN2, TXNRD1 | ENPP1 2457/4885SIRT2 1152/4885SIRT1 444/4885 |
| US-11524010-B2 | Substituted quinazoline sulfonamides as thioredoxin interacting protein (TXNIP) inhibitors | TXN, TXNL1, TXN2 | ENPP1 2704/4885SIRT2 741/4885SIRT1 276/4885 |
| US-20210369713-A1 | SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS | TXN, TXNL1, TXN2 | ENPP1 2704/4885SIRT2 741/4885SIRT1 276/4885 |
| US-20230172932-A1 | SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS | TXN, TXNL1, TXN2 | ENPP1 2704/4885SIRT2 741/4885SIRT1 276/4885 |
| US-11752153-B2 | Substituted quinazoline sulfonamides as thioredoxin interacting protein (TXNIP) inhibitors | TXN, TXNL1, TXN2 | ENPP1 2704/4885SIRT2 741/4885SIRT1 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.